The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
3,858
To assess the difference in event free survival and overall survival (subject to stand-alone or combined/meta-analysis) between postmenopausal women with HR +ve early BC who switched from tamoxifen to anastrozole and those who continued on tamoxifen.
To assess the difference in event free survival & overall survival (subject to stand-alone or combined/meta-analysis) plus side effects between postmenopausal women with HR+ve early BC who switched from tam to anastrozole and those who continued on tam.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Amstetten, Austria
Research Site
Bad Ischl, Austria
Research Site
Baden, Austria
Research Site
Bregenz, Austria
Research Site
Bruck/Mur, Austria
Research Site
Dornbirn, Austria
Research Site
Eisenstadt, Austria
Research Site
Feldbach, Austria
Research Site
Feldkirch, Austria
Research Site
Freistadt, Austria
...and 42 more locations